Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients

The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Patients treated with erlotinib experience different drug responses. The effect of germline mutations on therapeutic r...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Pharmacol
Main Authors: Wang, Cong, Chen, Fang, Liu, Yichen, Xu, Qingqing, Guo, Liang, Zhang, Xiaoqing, Ruan, Yunfeng, Shi, Ye, Shen, Lu, Li, Mo, Du, Huihui, Sun, Xiaofang, Ma, Jingsong, He, Lin, Qin, Shengying
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2018
Teme:
Pharmacology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5904969/
https://ncbi.nlm.nih.gov/pubmed/29695969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00360
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki